As a result, it is known as a “diamond mutation.” In 2007, the EML4-ALK fusion type was first discovered in NSCLC and confirmed to be a driver gene in lung cancer.[7] The incidence of ALK fusion-positive NSCLC is about 5%, with no significant difference between Eastern and Western populations.[8] ALK-TKIs, such as alectinib, crizotinib, and lorlatinib, have been shown to be significantly more effective than chemotherapy.[8–10]. This evidence concerns the gene ALK and non-small cell lung carcinoma.